Synairgen plc Directorate Change, Annual Report & Notice of AGM (6152W)
April 18 2019 - 4:20AM
UK Regulatory
TIDMSNG
RNS Number : 6152W
Synairgen plc
18 April 2019
Synairgen plc
('Synairgen' or the 'Company')
Directorate Change, Posting of Annual Report, and Notice of
AGM
Southampton, UK - 18 April 2019: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, today announces
that Paul Clegg has notified the Company of his intention to retire
from the Board as a non-executive director after the Company's 2019
Annual General Meeting on 3 June 2019. Iain Buchanan, non-executive
director, will take on the Chairmanship of the Remuneration and
Nomination Committee from that date.
Synairgen also announces that it has posted its Annual Report
and Accounts for the twelve months ended 31 December 2018 to its
shareholders together with the Notice of Annual General Meeting
("AGM"). The Company's AGM will be held at the offices of Fladgate
LLP, 16 Great Queen Street, London WC2B 5DG on 3 June 2019 at 11
am.
Simon Shaw, Chairman of Synairgen, said: "On behalf of the
Board, and personally, I would like to thank Paul for his
significant contribution and advice to Synairgen over the last 10
years and for his Chairmanship of the Remuneration and Nomination
Committee. We wish him well for the future."
The Annual Report and Notice of AGM are also available on the
Company's website www.synairgen.com.
- Ends -
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Alice Lane (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development.
Synairgen is currently conducting a two-part Phase II trial
evaluating SNG001, the Company's inhaled interferon beta (IFN-beta)
product. The Phase II trial, called SG015, has been designed to
assess the safety of SNG001 in COPD patients and its clinical
benefit in these patients when they have a cold or flu infection, a
major driver of COPD exacerbations.
Core to Synairgen's business strategy is the realisation of
value via licensing transactions. In August 2015 the Company
entered into a collaboration with Pharmaxis to develop an oral
LOXL2 inhibitor to reduce fibrosis in patients with idiopathic
pulmonary fibrosis (IPF). In December 2017, the collaboration
agreement was amended as Pharmaxis took on full responsibility for
the programme, with Synairgen receiving a GBP5 million upfront
payment and a share of at least 17% (net of allowable expenses) of
any receipts from any onward licensing by Pharmaxis of the LOXL2
inhibitors in fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKFDDFBKKAQD
(END) Dow Jones Newswires
April 18, 2019 04:20 ET (08:20 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2023 to Apr 2024